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Abstract
We report a case of fatal disseminated infection with Cryptococcus gattii in a patient from New Mexico. The patient had no
history of recent travel to known C. gattii-endemic areas. Multilocus sequence typing revealed that the isolate belonged to
the major molecular type VGIII. Virulence studies in a mouse pulmonary model of infection demonstrated that the strain
was less virulent than other C. gattii strains. This represents the first documented case of C. gattii likely acquired in New
Mexico.
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Introduction
Cryptococcus gattii was first isolated from a pediatric patient in the
Congo [1], and environmentally from various species of Eucalyptus
trees in Australia, where rural aboriginals have frequently been
reported with infection [2]. It has since been reported from
eucalyptus and other trees in tropical and subtropical regions
including southern California, South America, parts of Africa and
Southeast Asia [3,4]. Before 1999, C. gattii infections were only
rarely reported from temperate climates of North America [5,6];
however, since 1999, an outbreak of C. gattii infections has been
reported from British Columbia (BC), and more recently from the
U.S. Pacific Northwest (Washington and Oregon) [7–9]. Although
C. gattii was previously believed to be a tropical fungus, these
outbreaks demonstrate a larger ecological niche. Investigations
into the source of the outbreak in the temperate climate of
Vancouver Island and the Pacific Northwest (PNW) provide
evidence that decaying wood from tree hollows, soil, fresh and
saltwater may all be sources of C. gattii [8–10].
C. neoformans and C. gattii are the only two major species of the
genus Cryptococcus considered to be pathogenic in humans. Prior to
the AIDS epidemic, cryptococcal infections were rare. Since the
molecular characterization of C. neoformans and C. gattii and
classification into separate species, ecological and clinical differ-
ences have been reported. C. gattii tends to be seen clinically in
immunocompetent patients, although the spectrum of infection
can involve immunocompromised patients as well, whereas C.
neoformans is primarily an opportunistic pathogen. Both C. neofor-
mans and C. gattii have a propensity to cause pulmonary and
central nervous system (CNS) disease. In patients from Papua New
Guinea and Australia, C. gattii is more likely than C. neoformans to
cause cryptococcomas in the lung and brain, which may be
mistaken for malignancies (as in this case) or abscesses [11,12].
Furthermore, whereas the outbreak strain identified in BC/PNW
more commonly presents with a respiratory syndrome, non-
outbreak strains appear to present more commonly with CNS
infection [12,13].
The onset of cryptococcal infection is often subacute and
nonspecific, with headache being the most common presenting
symptom [14]. Compared to infections with C. neoformans, patients
with C. gattii cerebral involvement were found to have more severe
neurological sequelae such as hydrocephalus and focal CNS
findings, including ataxia, hearing loss, altered mentation,
papilledema, and higher intracranial pressures often requiring
surgical procedures for management. Infections due to C. gattii
follow a prolonged clinical course and are slower to respond to
antifungal therapy; however mortality does not appear to be
higher than C. neoformans infections [15,16].
We report the first documented case of C. gattii infection in New
Mexico, from a patient without a recent history of travel to a
known C. gattii-endemic area. Because the patient was immuno-
competent and New Mexico is not currently known to be a C.
gattii-endemic region, the infection went unrecognized until
autopsy.
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Results
Clinical Presentation
The patient was a 56-year-old Hispanic man who was brought
to the emergency room (ER) in late April 2010 for evaluation of a
2.5-month history of intermittent, progressively worsening head-
ache. The patient was noted to have mild confusion. He reported
no fever, chills, dyspnea, nausea, vomiting or diarrhea. He had
returned home in February 2010 after release from a two-month
incarceration in a state prison in Santa Rosa, NM. Upon entering
his home, he found that his dogs had expired, and his house was
extensively contaminated with dog feces. Several days after
cleaning his house, he reported experiencing a headache which
worsened over the next 2.5 months. In the ER, the patient was
afebrile and his physical and neurological exam was unremark-
able. Initial serum laboratory tests indicated mild leukocytosis
(WBC 11.66109/L, normal range 4–10.6), and hyponatremia
(sodium 128 mmol/L, normal range 137–145). A chest radio-
graph showed a focal infiltrate or mass estimated to be 468 cm in
the lingula as well as additional perihilar infiltrates, particularly in
the right upper lobe. A computed tomography of the head without
contrast revealed no evidence of focal lesions, and an opacified left
maxillary sinus suggestive of sinusitis. The patient was begun on
empiric ceftriaxone and azithromycin for possible community-
acquired pneumonia, and admitted for further evaluation of
headache and confusion.
The patient’s prior medical history included hypertension,
diabetes, and depression. His medication list included lisinopril,
naproxen, hydrocodone/acetaminophen, and lorazepam. His
family history was unremarkable. The patient had a one-year
history of smoking but had quit in December 2009. He drank
alcohol rarely and denied the use of recreational drugs. The
patient was born and lived alone in the same house which was
located in the South Valley area of Albuquerque, NM. In his
home, he was reported to have burned firewood for heat. There
was a chicken coop on his property where a relative raised
chickens. He was employed as a sanitation truck driver. The
patient rarely traveled, other than the recent incarceration in
Santa Rosa, NM, and has never left the state of New Mexico. The
patient did note a 30-pound weight loss during his two months of
incarceration.
Further testing included HIV antibody ELISA, which was
negative; CD4 T-cell count was 560 cells/mm
3. Magnetic
resonance imaging of the brain revealed a sub-centimeter focus
of restricted diffusion in the left global pallidus that was consistent
with acute or sub-acute ischemic infarct, and a focus of abnormal
increased T2 signal intensity in the sub-cortical white matter. A
chest CT revealed the previously noted lingular mass, measuring
5.564.5 cm. Bilateral patchy multifocal nodular densities were
identified in bilateral upper and lower lobes, some of which had a
ground glass appearance. No significant adenopathy was identi-
fied. A PET-CT scan revealed a metabolically active mass in the
lingual; clinically suspected to be a malignancy. During the course
of the patient’s initial hospitalization of six days, the patient’s
mental status, hyponatremia, and overall clinical status improved.
Further evaluation of the lung mass was planned as part of an
outpatient management plan.
Ten days later, the patient was brought back to the emergency
room for evaluation of altered mental status. Upon arrival to the
ER, the patient was initially responsive only to noxious stimuli and
was found to be severely hypertensive (BP 201/126) and
tachycardic (P 129). He responded to naloxone and labetalol.
On exam, pupils were noted to be initially unequal (right 2 mm,
left 4 mm) but were reported equal after administration of
naloxone. After becoming more alert, the patient stated that he
had developed progressive, severe weakness over the past 3 weeks
resulting in difficulty lifting his extremities. He was essentially bed-
bound as a result. Furthermore, he reported intermittent, severe
headache with associated neck pain. The patient also noted
‘‘ringing in his ears’’ for the preceding four days, with difficulty
hearing anything else.
A portable chest radiograph revealed no change in the lingular
mass and new scattered areas of patchy infiltrate in both lung
fields. A head CT without contrast was unchanged from the prior
CT. Empiric intravenous vancomycin and piperacillin-tazobactam
were given after the collection of blood cultures for treatment of
possible healthcare-associated pneumonia. A repeat brain MRI
the next day was also unchanged. Empiric azithromycin was
added on day two of the patient’s hospitalization. The patient was
found unresponsive on hospital day two and expired shortly
thereafter.
Microbiologic and Pathological Examination Identifies C.
gattii
A post-mortem examination was performed. Sections through
the cerebral hemispheres demonstrated multiple, small vesicular
lesions predominantly in the bilateral basal ganglia and also
scattered throughout the bilateral white matter tracts (Figure 1A).
No lesions were present in the cerebellum or brainstem. On
histologic exam, sections from the bilateral basal ganglia showed
multiple, cleared-out spaces containing numerous round yeast
forms (Figure 1B).
In the lungs, a 7.565.064.0 cm, well-circumscribed yellow-tan
mass was present in the lingula. Diffuse, bilateral, tan, ill-defined
lesions were also present in all lobes of the lungs (Fig. 2A). Lung
sections revealed occasional scattered, interstitial and intravascular
clusters of encapsulated round yeasts morphologically consistent
with Cryptococcus species (Figure 2B). Significant pulmonary edema
with scattered acute inflammatory cells and macrophages were
also present. Gomori methenamine silver (GMS) and mucicarmine
stains of lung tissue revealed scattered yeasts.
Blood cultures collected on admission to the hospital as well as
postmortem bacterial and fungal cultures of the lungs and heart
blood grew Cryptococcus species, identified as C. gattii by the Fungus
Testing Laboratory (University of Texas Health Science Center,
San Antonio) on June 23, 2010.
Multilocus Sequence Typing (MLST) Identifies the VGIII
Molecular Genotype
To delineate the relationship between the clinical isolate R4569
and isolates from the C. gattii emergence in the Pacific Northwest
U.S. and British Columbia (PNW), MLST analysis, using the
seven loci of the consensus MLST typing scheme was performed
[17]. The isolate R4569 was genotyped as belonging to the major
molecular type VGIII, which is different from the VGII major
molecular type of the majority of the emerging isolates from the
Pacific Northwest. To more accurately pinpoint the origin of
isolate R4569, the phylogenetic relationships between a number of
reference C. gattii isolates from the U.S. and neighboring Mexico
were analyzed and a neighbor-joining dendrogram was construct-
ed based on the seven concatenated MLST sequences (Figure 3,
Table 1). The VGIII isolates investigated fell into three distinct
clades, one containing isolates exclusively from Mexico, and two
containing a mixture of Mexican and U.S. isolates. The New
Mexico isolate (R4569) was more closely related to U.S. isolates
and this grouping had a high bootstrap value.
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R4569 is Less Virulent in Mice than Other Known C. gattii
Strains
To assess the virulence potential of the R4569 isolate in an animal
model, BALB/c mice were intranasally infected with 16105 CFU
of R4569. Separate cohorts of mice were also infected with C. gattii
strains R265 and R272, reference strains for VGIIa and VGIIb
molecular subtypes respectively, associated with the Vancouver
Island outbreak [18], as well as the C. neoformans reference strain
H99 [19]. All mice infected with C. gattii strain R265 and C.
neoformans strain H99 succumbed to infection with median survival
times of 27 days and 23.5 days, respectively (Figure 4a) similar to
previous studies [20,21]. Survival rates for mice infected with C.
gattii strains R272 and R4569 were significantly greater (87.5% and
100% survival, p,0.05) than mice infected with R265 or H99
(Figure 4a). The survival rate of mice challenged with C. gattii R272
strain was similar to earlier survival analysis using this strain [21]
(Wormley lab, unpublished observations). Nonetheless, no mice
infected with strain R4569 appeared ill by day 50 post-infection;
however, fungal burden determination from the lungs and brain of
mice at the termination of the experiment revealed the presence of
numerous viable yeasts in mice infected with strain R272 or R4569
(Figure 4a). Significantly fewer CFUs were cultured from the lungs
and brains of mice infected with strain R4569 than those infected
with strain R272. Furthermore, histological examination revealed
greater inflammation in the lungs of mice infected with strain R272
compared to strain R4569 (Figure 4b). Many yeast cells of strain
R4569 were confined within activated ‘‘foamy’’ macrophages, that
are indicative of increased intracellular killing of cryptococci by
macrophages and thus control of fungal replication (Figure 4b,
arrows) [22,23]. Altogether these results suggest that strain R4569 is
less virulent than the VGII reference isolates in a mouse model of
pulmonary infection or, alternatively, an enhanced capacity of mice
to limit the growth of R4569 yeast.
Discussion
Our findings represent the first documented case of C. gattii
infection believed to have been acquired in New Mexico. The
Figure 1. Postmortem examination of the brain demonstrates
cryptococcal lesions. a. On gross examination, sections through the
cerebral hemispheres demonstrated multiple, small vesicular lesions
predominantly in the bilateral basal ganglia and additional lesions
scattered throughout the bilateral white matter tracts. No lesions were
present in the cerebellum or brainstem. b. On histopathologic exam,
hemotoxylin/eosin stained sections of the vesicular lesions showed
diffuse clusters of yeast cells.
doi:10.1371/journal.pone.0028625.g001
Figure 2. Postmortem examination of the lungs reveals
multiple cryptococcal lesions. a. Postmortem examination of the
lungs revealed multiple yellow-tan ill-defined masses throughout all
lobes of the lungs. b. Histopathologic examination of the lungs
demonstrated scattered interstitial and intravascular encapsulated
yeasts morphologically consistent with Cryptococcus species.
doi:10.1371/journal.pone.0028625.g002
Fatal Disseminated C. gattii in NM
PLoS ONE | www.plosone.org 3 December 2011 | Volume 6 | Issue 12 | e28625
source of C. gattii infection in this patient remains unknown. The
patient had no travel history to a known endemic region, and
while C. gattii infection in domestic animals has been documented,
these have been reported in animals residing in areas endemic to
C. gattii [8,24]. New Mexico is an arid region covered mostly by
mountains, plains, and desert, with little annual rainfall and
relatively low humidity. Since 2002, there has been an increase in
precipitation around the Albuquerque area, which was highest
between 2004 and 2008 compared to the 30-year normal
averages. In addition, the annual temperature has also been
above average, with a median temperature of 58 degrees
Fahrenheit [25]. New Mexico has regions similar to those in
Mexico known to harbor C. gattii [26–29], whereas the foothills of
the Rocky Mountains, which run through Albuquerque, may
represent a more temperate climate niche. Environmental
sampling in the Pacific Northwest demonstrated that C. gattii has
established ecological niches in trees other than Eucalyptus,
including species of fir, maple, alder, cedar, spruce, pine and
oak trees [10,24]. In another environmental surveillance study,
certain species of cacti in Puerto Rico were also found to harbor C.
gattii [4,30]. Both of these sources could potentially serve as an
ecological niche for C. gattii in New Mexico. Further environmen-
tal surveillance of the patient’s residential area was not conducted
(as resources to pursue this are not available).
In general, cryptococcal disease appears to be rare in New
Mexico. Between 2003 and 2007, we estimate there were at least
one to two confirmed cases of cryptococcal disease in the
Albuquerque area, which is home to the four largest hospitals in
New Mexico. Starting in 2008, the number of confirmed cases
increased with three cases in 2008, eight cases in 2009 and at least
five cases to date in 2010. The autopsy report of this patient led to
the diagnosis of disseminated C. gattii infection. However, due to
the initial clinical impression of lung malignancy, the patient’s
immunocompetent status and lack of a travel history did not
heighten clinical awareness of a cryptococcal infection in time to
initiate antifungal therapy. Because the clinical presentation was
most suggestive of a lung mass or malignancy, and the actual
diagnosis is infrequently seen in this area, further testing for
invasive fungal infection was not performed. The patient had
widely disseminated infection with extensive inflammation, and
likely succumbed to overwhelming systemic infection and sepsis,
rather than elevated intracranial pressure with brainstem herni-
ation, based on post-mortem findings. To date, C. gattii infections
in the United States have been reported in Washington, Oregon,
California, and North Carolina, in which all patients had some
geographical exposure to endemic regions. [7,8,31,32] The case
reported here is similar to another case report of a 44-year-old
immunocompetent man in Japan with C. gattii CNS disease who
had no history of recent overseas travel [33]. Although this strain
was VGIIa, similarities to this case include the endemic nature of
the infection, and clinically, the mass lesion was also initially
suspected to be a tumor. Cases such as these, in which
immunocompetent patients who lack geographical risk factors
living in non-endemic areas are acquiring C. gattii infections,
suggest that there might be a broader distribution of the pathogen
than is currently recognized.
The non-VGII genotype of this C. gattii isolate indicates it does
not represent the migration of the PNW outbreak strains
southward to New Mexico. Because of the lack of a clonal
relationship to isolates from Mexico, it also does not likely
represent the recent migration of C. gattii isolates northward from
Mexico. Rather, this isolate likely represents the emergence of a
clonal genotype that, based on geography of the common isolates
has probably persisted in the U.S. for quite some time. A recent
Figure 3. Neighbor joining dendrogram showing genotype VGIII isolates from the Pacific Nothwest of the US, California and
Mexico. The isolate from New Mexico is more closely related to isolates from California, Washington and Oregon than to most of the isolates from
Mexico, possibly indicating a US enriched clade of C. gattii VGIII. Significant bootstrap values are shown.
doi:10.1371/journal.pone.0028625.g003
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literature review [24] reported that VGIII isolates of C. gattii are
most common in South America but they are also found in North
America, Central America, Australasia and Southeast Asia. It was
also recently reported that the majority of C. gattii isolates from
HIV+ patients in California are VGIII [31]. Isolates of the
genotype VGIII have not been found so far in environmental
samples from British Columbia [10] nor from the U.S. PNW (S.
Lockhart, unpublished results) but VGIII environmental isolates
have been infrequently found in the U.S. in association with
eucalyptus trees [34]. Subtype VGIII isolates had not been
reported from the PNW emergence until a single isolate was
reported from Washington in 2009 [18,32]. Subsequently, human
and veterinary isolates were reported from Washington, Oregon,
and California, dating back to as early as 1992 [35]. It will be
important to monitor further for the emergence of this genotype in
other parts of the southwestern U.S.
C. gattii causes granulomatous pulmonary and disseminated
disease in mouse inhalation models of infection, irrespective of the
mouse strain used. In terms of genotypic variation in virulence,
VGIIa isolates from the U.S. and from the Vancouver outbreak
are more virulent in mice than VGIIb isolates from either region
[36–39]. Our results suggest that the VGIII isolate R4569 is less
virulent than either of the VGII strains tested. The morbidity
observed in mice given an experimental infection with the VGIII
isolate R4569 is similar to the morbidity observed in mice
experimentally infected with other VGIII clinical isolates. Of the
C. gattii cases reported to the CDC between 2004 and 2010, 50%
were molecular type VGIIa, 10% were VGIIb, and only 3% were
VGIII [40]. While the relationship of mouse virulence to human
disease is unclear, it has been demonstrated that C. gattii infections
are immunologically similar in mice and infected humans with
respect to cytokine profiles [37,41]. C. gattii replicates intracellu-
larly within macrophages. It has been demonstrated that
intracellular replication rate within murine macrophages in vitro
is correlated with in vivo virulence in mice [38,42,43]. VGIIa
isolates replicate more quickly in macrophages in vitro and are
more virulent in vivo than VGIIb isolates. Furthermore, intracel-
lular replication rate in murine macrophages correlates very highly
with the intracellular replication rate in human macrophages,
suggesting there might be a correlation between genotype and
human virulence and disease [43]. Additional studies comparing
the intracellular growth rate of C. gattii R4569 and other isolates
within murine and human macrophages will be needed to support
this hypothesis. The major clinical point from these in vivo studies
is that despite strain R4569 being less virulent in this mouse
infection model is that it is still highly capable of causing severe
morbidity and mortality, particularly in the absence of timely
diagnosis and therapy.
Table 1. Isolates used for comparison in this study.
MLST allele
Isolate State CAP59 GPD1 LAC1 PLB1 SOD1 URA5 IGS1 Source Subtype Reference
B7415 CA 18 3 3 6 40 19 1 alpaca VGIII 29
B8964 CA 18 3 3 6 40 19 1 human VGIII This study
B8212 WA 18 3 3 6 40 19 1 human VGIII 29
B8516 OR 18 3 3 6 40 19 1 cat VGIII This study
R4569 NM 18 3 3 20 28 25 1 human VGIII This study
B7495 CA 18 3 32 20 40 23 1 human VGIII 29
B8260 WA 29 9 2 4 28 19 18 cat VGIII 29
WM 1826 Mexico 18 3 3 6 40 19 1 human VGIII 43
B8262 CA 18 3 3 34 38 19 1 human VGIII 29
WM 1815 Mexico 18 3 22 6 28 19 1 human VGIII 43
WM 1819 Mexico 18 3 32 20 40 23 1 human VGIII 43
WM 1814 Mexico 29 7 2 4 28 21 5 human VGIII 43
WM 1823 Mexico 29 7 2 4 28 21 5 human VGIII 43
WM 1618 Mexico 18 3 22 6 28 19 1 human VGIII 43
WM 1635 Mexico 18 3 22 21 32 19 1 human VGIII 43
WM 1620 Mexico 18 3 20 17 28 29 23 human VGIII 43
WM 1824 Mexico 18 3 20 17 32 29 1 human VGIII 43
WM 1631 Mexico 18 3 22 17 32 19 23 human VGIII 43
WM 1811 Mexico 35 3 22 20 41 28 5 human VGIII 43
WM 1812 Mexico 35 3 22 20 41 28 5 human VGIII 43
B6253 CA 16 15 5 5 45 12 3 dolphin VGI 44
B8263 CA 16 5 5 5 32 12 3 human VGI 29
B8551 OR 16 14 5 5 32 12 3 human VGI This study
B7394 WA 2 6 4 2 15 2 10 cat VGIIb 29
B7395 WA 1 1 4 1 14 7 4 dog VGIIa 29
B7432 OR 6 6 4 1 15 2 15 human VGIIc 29
doi:10.1371/journal.pone.0028625.t001
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Based on the few previous reports [18,32,35,38] there may be a
low level of C. gattii infection in the U.S. due to VGIII isolates that
may be unrecognized outside of HIV+ patients. However, the
underlying level of infection due to C. gattii is currently unknown
because many of the cases of cryptococcosis in the U.S. are
diagnosed using an antigen test and most cases outside of the
Pacific Northwest are assumed to be caused by C. neoformans. The
heterogeneity of the VGIII isolates in this study, as compared to
the almost exclusively clonal nature of the current VGII PNW
emergence isolates, would be consistent with a long-term presence
in the U.S. and a possibly unrecognized, long term, low level,
endemicity. It is also interesting to note that among HIV+ patients
in California in the 1990’s almost all of the infections due to C.
gattii were caused by isolates of the VGIII genotype [31,44], where
globally VGIII isolates were more often found in the non-
immunocompromised patient population [45,46]. We therefore
support speciation of Cryptococcus clinical isolates due to the
implications for public health and for understanding the
epidemiological distribution of this fungal pathogen. In addition,
there is epidemiological evidence that there are substantive
differences in the clinical presentation of C. gattii and the course
of disease compared to C. neoformans [13].
As infections due to C. gattii increase both in the United States
and worldwide, epidemiologic surveillance will play an important
role in identifying new ecological niches or reservoirs for this
emerging fungal pathogen. Since not all clinical and reference
laboratories are equipped to differentiate between C. gattii and C.
neoformans, a heightened clinical awareness of the disease will be
required to prompt further identification and genotyping to track
the distribution of C. gattii.
Materials and Methods
Approvals and Ethics Statement
The authorized representative of the patient in this manuscript
has given written informed consent (as outlined in the PLoS
Figure 4. Strain R4569 is hypovirulent compared to VGII strains R265 and R272. a. Eight mice per group were intranasally inoculated with
16105 CFU of each strain and monitored for disease. Mice infected with C. neoformans strain H99 or C. gattii strain R265 had mean survival times of
23.5 and 27 days, respectively. 87.5% of mice survived infection with R272, and all mice infected with R4569 survived. Survival curves between R272
and R4569 were not significantly different, but fungal burden determination at day 50 post-infection revealed significantly less yeast in the lungs and
brains of mice infected with R4569 (p,0.05, Student’s t-test). b. Sections of lung from mice infected with R272 show greater numbers of organisms as
compared to infections from R4569. There are also increased numbers of lymphocytes and macrophages around aggregates of yeast with R272 than
observed with R4569. Additionally, yeasts are found within ‘‘foamy’’ macrophages with R4569 (arrows) suggesting greater control of the infection.
doi:10.1371/journal.pone.0028625.g004
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consent form) to publication of their case details. These animal
experiments were approved by The University of Texas at San
Antonio Institutional Animal Care and Use Committee (IACUC),
approved protocol number MU021-11/1A2, and mice were
handled according to IACUC guidelines. An IRB waiver was
provided by the New Mexico Veterans Healthcare System Office
of Research.
Microbiologic Identification
Fungal identification was performed at the Fungus Testing
Laboratory (University of Texas Health Science Center, San
Antonio) using canavanine-glycine-bromthymol blue (CGB) agar
and URA5 sequencing as previously described [5].
Multilocus Sequence Typing
The isolate was subtyped using The ISHAM consensus
multilocus sequence typing (MLST) scheme [17]. The URA5,
IGS, PLB1, SOD1, GPD1, LAC1, and CAP59 gene fragments were
amplified as described by Meyer and colleagues [17]. Briefly,
isolates were grown on YPD plus 0.5% NaCl and DNA was
isolated using the UltraClean DNA Isolation Kit as described by
the manufacturer (MO BIO Laboratories, Carlsbad, CA). Gene
fragments were amplified and sequenced in both directions using
the primers of Meyer et al [17]. Allele and sequence types were
assigned according to the C. gattii MLST database at mlst.mycolo-
gylab.org. The compiled sequences were compared to C. gattii
sequences collected during the U.S. PNW surveillance (SRL) or
during a previous surveillance in Mexico [W. Meyer, unpublished
data]. Phylogenetic relationships, the neighbor-joining tree and
bootstrap values were calculated using the Mega 4.1 software
package [47]. All generated allele and sequence types of the seven
genetic loci studied herein are accessible at the C. gattii MLST
database at mlst.mycologylab.org.
Mouse Pulmonary Model of Infection
Female BALB/c (H-2d) mice, four to six weeks of age (National
Cancer Institute/Charles River Laboratories), were used through-
out these studies. Mice were housed at The University of Texas at
San Antonio Small Animal Laboratory vivarium and handled
according to guidelines approved by the Institutional Animal Care
and Use Committee.
Pulmonary cryptococcal infections were initiated by nasal
inhalation as previously described [48]. Briefly, BALB/c mice
(eight per group) were anesthetized with 2% isoflurane using a
rodent anesthesia device (Eagle Eye Anesthesia, Jacksonville, FL)
and then given an inoculum of 16105 colony forming units (CFU)
of C. neoformans strain H99 or C. gatti strains R265 (VGIIa), R272
(VGIIb), or R4569 (isolate from this case) in 50 ml of sterile PBS
introduced directly into the nares. The strains R265 and R272
were provided by Joseph Heitman (Duke University Medical
Center, Durham, NC). The inocula used for nasal inhalation were
verified by quantitative culture on yeast peptone dextrose (YPD)
agar. The mice were fed ad libitum and monitored by inspection
twice daily. Mice were either euthanized when moribund or at day
50 post-inoculation. For histopathology (three mice per group),
lungs were transcardially perfused with PBS then inflated with
10% formalin via an intratracheal catheter. Lungs were tied off,
dissected, and stored in formalin until paraffin embedding,
sectioned, and stained by hematoxylin and eosin (Histology
Laboratory at The University of Texas Health Science Center at
San Antonio). For colony-forming unit (CFU) determination in
surviving mice (four to five mice per group), lung tissues were
excised using aseptic technique, homogenized in 1 ml of sterile
PBS, and cultured by 1:10 dilutions on YPD agar supplemented
with chloramphenicol (Mediatech, Inc., Herndon, VA). CFUs
were enumerated following incubation at 30uC for 48 h.
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